Study: Misuse Of Patent System Affecting Health System In Australia 10/04/2013 by Intellectual Property Watch Leave a Comment Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Research from the University of Melbourne has found that patents may be keeping pharmaceuticals expensive in Australia, but said that most of the patents are being taken out by companies that are not the originators of the drugs. The study attempts to counter concern that pharmaceutical companies are inappropriately extending their monopoly position by “evergreening” blockbuster drugs, in a misuse of the patent system. The study claims to have studied 15 of the costliest drugs in Australia over the last 20 years. They found an average of nearly 50 patents per drug, and three-quarters of these owned by companies other than the originators. “The 15 drugs in our study cost the country more than $17 billion over two decades. There are suspicions that abusive patenting by the big pharmaceutical companies is keeping that cost high. Our research shows that patenting by generic manufacturers and other players may be just as important.” According to the study, the research was funded by the Australian Research Council, as “Discovery Project DP0987570, Chief Investigators: AF Christie, DM Studdert, P McIntyre, C Dent. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” [corrected] The study is available here. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "Study: Misuse Of Patent System Affecting Health System In Australia" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.